CD388 demonstrates prophylactic reduction of viral replication in the upper respiratory tract, or URT, and the incidence of PCR-confirmed influenza infection: The Phase 2a prophylactic efficacy results are based on 56 subjects enrolled in the trial, with 28 subjects receiving a single dose of CD388 (150 mg) and 28 subjects receiving a placebo. Cloudbreak Oncology Program and Our DFC Development Candidate CBO421 Statistical significance was pre-determined using a Wilcoxon rank-sum test with a one-sided type- ...

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The effective time of the reverse stock split will be 5 p.m. ET on ...

- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer mouse model - Late-breaking CBO421 data demonstrates improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjuga ...

The UK MHRA approval follows approvals by the U.S. FDA and the European CommissionCidara is entitled to receive a milestone payment of approximately $2.8 million from Mundipharma SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) ha ...

Recently Issued and Recently Adopted Accounting Pronouncements | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------|-------|--------|-------|--------|-------|-------|-------|-------| | | | | | | | | | | | September 30, 2023 | | | | | | | | | | Assets: | | | | | | | | | | Cash and money market accounts | $ | 48,670 | $ | 48,670 | $ | | — $ | — | | Total assets at fair value | $ | 48,670 | $ | 48,670 | $ | | — $ | — | | December 31, 2022 | | | | | | | | | | Assets: ...

14 Common stock reserved for future issuance is as follows (in common stock equivalent shares): 7. EQUITY INCENTIVE PLANS | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------|--------------------|----------|----------------------------|--------------------------------------------------------------|---------------|----------------------------------------| | | Number of Shares | Exercise | Weighted \nAverage Price | Average \nWeighted Remaining \nContract ...

Common Stock The Company had 200,000,000 shares of common stock authorized as of March 31, 2023. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company's capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company's board of directo ...

Overview of Systemic Fungal Infections and the Antifungal Market CIDARA THERAPEUTICS, INC. Influenza is a respiratory infection caused by influenza viruses. The influenza virus can cause mild to severe illness, and at times can lead to death. Young children, adults older than 65 years, pregnant women and immunocompromised patients are more prone to infection, but even healthy people are at risk of infection with seasonal influenza. The primary preventive measure to protect against influenza is the seasonal ...

1 CORPORATE PRESENTATION LEADING THE SCIENCE OF PROTECTION FORWARD- LOOKING STATEMENTS 2 These slides contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "may," "will," "estimate," "plan", "anticipate," "expect," "potential," "could," "project," and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1537286 (State or Other Juris ...